Synthesis and preliminary evaluation of 18-18F-fluoro-4-thia- oleate as a PET probe of fatty acid oxidation

Journal of Nuclear Medicine

Volumn 51, Issue 8, 2010, Pages 1310-1317

  DeGrado, Timothy R ^a   Bhattacharyya, Falguni ^b   Pandey, Mukesh K ^a   Belanger, Anthony P ^a   Wang, Shuyan ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Fatty acid oxidation; Myocardial metabolism; PET

Indexed keywords

16 FLUORO 4 THIA PALMITATE F 18; 18 FLUORO 4 THIA OLEATE F 18; ETOMOXIR; FATTY ACID; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; 16 FLUORO 4 THIAPALMITIC ACID; 16-FLUORO-4-THIAPALMITIC ACID; 18 FLUORO 4 THIAOLEIC ACID; 18-FLUORO-4-THIAOLEIC ACID; DIAGNOSTIC AGENT; ENZYME INHIBITOR; EPOXIDE; OLEIC ACID; PALMITIC ACID DERIVATIVE; SULFIDE; THIOKETONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG ANALYSIS; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; FATTY ACID OXIDATION; FEMALE; HEART; LIVER; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIOACTIVITY; RADIOCHEMISTRY; RAT; SKELETAL MUSCLE; ANIMAL; DOSE RESPONSE; HEART MUSCLE; METABOLISM; METHODOLOGY; OXIDATION REDUCTION REACTION; SCINTISCANNING; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPOXY COMPOUNDS; FATTY ACIDS; FEMALE; HEART; MYOCARDIUM; OLEIC ACIDS; OXIDATION-REDUCTION; PALMITATES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SULFIDES; THIONES; TISSUE DISTRIBUTION;

EID: 77956196117     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.074245     Document Type: Article

References (38)

1. Wang W, Lopaschuk GD. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Expert Rev Cardiovasc Ther. 2007;5:1123-1134. (Pubitemid 350303047)
2. Fragasso G, Spoladore R, Bassanelli G, et al. New directions in the treatment of heart failure: targeting free fatty acid oxidation. Curr Heart Fail Rep. 2007;4:236-242.
3. Tuunanen H, Kuusisto J, Toikka J, et al. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the α-tropomyosin gene: a positron emission tomography study. J Nucl Cardiol. 2007;14:354-365.
4. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:230-234.
5. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008;2:1101-1113.
6. You M, Crabb DW. Recent advances in alcoholic liver disease II: minireview - molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1-G6. (Pubitemid 38802112)
7. Kotronen A, Seppala-Lindroos A, Vehkavaara S, et al. Liver fat and lipid oxidation in humans. Liver Int. 2009;29:1439-1446.
8. Young ME, Guthrie PH, Razeghi P, et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes. 2002;51:2587-2595.
9. Bugger H, Abel ED. Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci (Lond). 2008;114:195-210.
10. Leonhardt M, Langhans W. Fatty acid oxidation and control of food intake. Physiol Behav. 2004;83:645-651.
11. Barsotti A, Giannoni A, Di Napoli P, Emdin M. Energy metabolism in the normal and in the diabetic heart. Curr Pharm Des. 2009;15:836-840.
12. 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: effects of hypoxia and composition of exogenous fatty acids. J Nucl Med. 2006;47:173-181.
13. Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441-2446. (Pubitemid 32493369)
14. 18F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation. Nucl Med Biol. 2000;27:221-231.
15. Renstrom B, Rommelfanger S, Stone CK, et al. Comparison of fatty acid tracers FTHA and BMIPP during myocardial ischemia and hypoxia. J Nucl Med. 1998;39:1684-1689.
16. 18F]fluoro-6-thia- heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids. J Nucl Med. 1991;32:1888-1896.
17. Stone CK, Pooley RA, DeGrado TR, et al. Myocardial uptake of the fatty acid analog 14-fluorine-18-fluoro-6-thia-heptadecanoic acid in comparison to β-oxidation rates by tritiated palmitate. J Nucl Med. 1998;39:1690-1696.
18. 14C-labeled substrates in humans. J Clin Invest. 1987;79:359-366.
19. Kanaley JA, Shadid S, Sheehan MT, Guo Z, Jensen MD. Relationship between plasma free fatty acid, intramyocellular triglycerides and long-chain acylcarnitines in resting humans. J Physiol. 2009;587:5939-5950.
20. Bergouignan A, Momken I, Schoeller DA, Simon C, Blanc S. Metabolic fate of saturated and monounsaturated dietary fats: the Mediterranean diet revisited from epidemiological evidence to cellular mechanisms. Prog Lipid Res. 2009;48:128-147.
21. Bergouignan A, Trudel G, Simon C, et al. Physical inactivity differentially alters dietary oleate and palmitate trafficking. Diabetes. 2009;58:367-376.
22. DeLany JP, Windhauser MM, Champagne CM, Bray GA. Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr. 2000;72:905-911.
23. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep. 2005;7:63-70.
24. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005;91:161-165.
25. Wambolt RB, Lopaschuk GD, Brownsey RW, Allard MF. Dichloroacetate improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol. 2000;36:1378-1385.
26. Knust EJ, Kupfernagel C, Stocklin G. Long-chain F-18 fatty acids for the study of regional metabolism in heart and liver; odd-even effects of metabolism in mice. J Nucl Med. 1979;20:1170-1175.
27. Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med. 1996;37:1723-1730.
28. Fox KA, Abendschein DR, Ambos HD, Sobel BE, Bergmann SR. Efflux of metabolized and nonmetabolized fatty acid from canine myocardium: implications for quantifying myocardial metabolism tomographically. Circ Res. 1985;57:232-243.
29. Livni E, Elmaleh DR, Barlai-Kovach MM, Goodman MM, Knapp FF Jr., Strauss HW. Radioiodinated β-methyl phenyl fatty acids as potential tracers for myocardial imaging and metabolism. Eur Heart J. 1985;(6 suppl B):85-89.
30. 11C] heptadecanoic acid: a new myocardial metabolic tracer for positron emission tomography. J Nucl Med. 1982;23:169-175.
31. DeGrado TR, Holden JE, Ng CK, Raffel DM, Gatley SJ. Beta-methyl-15-p- iodophenylpentadecanoic acid metabolism and kinetics in the isolated rat heart. Eur J Nucl Med. 1989;15:78-80. (Pubitemid 19054854)
32. 131I]iodo-9-telluraheptadecanoic acid, a potential imaging agent. J Med Chem. 1982;25:613-618.
33. Skrede S, Sorensen HN, Larsen LN, et al. Thia fatty acids, metabolism and metabolic effects. Biochim Biophys Acta. 1997;1344:115-131.
34. Ebert A, Herzog H, Stocklin GL, et al. Kinetics of 14(R,S)-fluorine-18- fluoro-6-thia-heptadecanoic acid in normal human hearts at rest, during exercise and after dipyridamole injection. J Nucl Med. 1994;35:51-56.
35. 18F]Fluoro-6- thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardium and skeletal muscle. Eur J Nucl Med Mol Imaging. 2002;29:1617-1622.
36. Jones PJ, Schoeller DA. Polyunsaturated:saturated ratio of diet fat influences energy substrate utilization in the human. Metabolism. 1988;37:145-151.
37. Noland RC, Woodlief TL, Whitfield BR, et al. Peroxisomal-mitochondrial oxidation in a rodent model of obesity-associated insulin resistance. Am J Physiol Endocrinol Metab. 2007;293:E986-E1001.
38. 18F]fluoro long chain fatty acid analogs show cytochrome P-450-mediated defluorination: implications for the design of PET tracers of myocardial fatty acid utilization. Int J Rad Appl Instrum B. 1992;19:389-397.